Intercept’s failed NASH candidate precipitated Alfasigma acquisition
Mohammed Hanefa Nizamudeen After the Following the failure of Intercept Pharmaceuticals' (ICPT) Ocaliva (obeticholic acid) for nonalcoholic steatohepatitis (NASH) in ...
Mohammed Hanefa Nizamudeen After the Following the failure of Intercept Pharmaceuticals' (ICPT) Ocaliva (obeticholic acid) for nonalcoholic steatohepatitis (NASH) in ...